MedTrace Logo

FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage

NCT06420011 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2025-10-27

No results posted yet for this study

Summary

FAITH study is a multicentre retrospective analysis study that aims to understand the burden of ICH related to FXa inhibitors and the current treatment approaches in country/countries where specific reversal agents are not available yet. The results of this analysis will improve our understanding of FXa inhibitor-related ICH, its socioeconomic impact and factors associated with negative outcomes in real-world settings. The insights gained can inform clinical decision making and potentially lead to strategies to optimise the use of FXa inhibitors, increase the availability of specific reversal agents and improve patient safety and outcomes.

Conditions

  • InTracranial Haemorrhage

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-08
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • Argentina
  • Brazil
  • Colombia
  • Mexico
  • Qatar
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06420011 on ClinicalTrials.gov